Skip to Content
Merck
All Photos(3)

Key Documents

MABN13

Sigma-Aldrich

Anti-Amyloid β42 Antibody, clone G2-13

clone G2-13, from mouse

Synonym(s):

Alzheimer disease, Alzheimer disease amyloid protein, Cerebral vascular amyloid peptide, Protease nexin-II, amyloid beta (A4) precursor protein, amyloid beta A4 protein, amyloid beta precursor protein, beta-amyloid peptide, human mRNA for amyloid A4 prec

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified antibody

clone

G2-13, monoclonal

species reactivity

human

species reactivity (predicted by homology)

mouse (based on 100% sequence homology)

technique(s)

ELISA: suitable
immunohistochemistry: suitable
western blot: suitable

isotype

IgG1κ

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... APP(351)

General description

The cerebral and vascular plaques associated with Alzheimer′s disease (AD) are mainly composed of amyloid beta peptides (Aβ). Aβ is derived from cleavage of the amyloid precursor protein (APP) and varies in length from 39 to 43 amino acids. Aβ [1-40], Aβ [1-42], and Aβ [1-43] peptides result from cleavage of APP after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last APP processing step. Aβ [1-40], [1-42] and [1-43] peptides are major constituents of the plaques and tangles that occur in AD. These Amyloid beta antibodies and peptides have been developed as tools for elucidating the biology of AD.

Specificity

This antibody recognizes human Amyloid β42 isoform at the C-terminus

Immunogen

Epitope: C-terminus
KLH-conjugated linear peptide corresponding to the C-terminus of Amyloid β42.

Application

Anti-Amyloid β42 Antibody, clone G2-13 is an antibody against Amyloid β42 for use in WB, IH, ELISA.
Immunohistochemistry Analysis: 1:300 dilution from a previous lot detected Amyloid β42 in Alzheimerdiseased cerebral cortex and hippocampus tissue.
ELISA: A representative lot of MABN12 antibody was used in a titer ELISA. Specificity of detection for Amyloid beta peptides is displayed below.


ELISA:
Research Category
Neuroscience
Research Sub Category
Neurodegenerative Diseases

Quality

Evaluated by Western Blot on human Alzheimer diseased brain tissue lysate.

Western Blot Analysis: 1 µg/ml of this antibody detected Amyloid β42 in 10 µg of human Alzheimer diseased brain tissue lysate.

Target description

4kDa Calculated

Physical form

Format: Purified
Protein G Purified
Purified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4, 150 mM NaCl) with 0.05% sodium azide and 1% BSA.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Analysis Note

Control
Human Alzheimer diseased brain tissue lysate

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ramune Morkuniene et al.
Journal of neurochemistry, 126(5), 604-615 (2013-06-12)
Beta amyloid (Aβ) oligomers are thought to contribute to the pathogenesis of Alzheimer’s disease. However, clinical trials using Aβ immunization were unsuccessful due to strong brain inflammation, the mechanisms of which are poorly understood. In this study we tested whether

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service